证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-17 | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | | 类别 | | □新闻发布会 □路演活动 | | | | □现场参观 | 其他 202 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-28 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|---------------------------------------------------------------|--------------------------------------------------------|-------|--------|------------------|-------| | 投资者关系活动 \n类别 | □特定对象调研 □媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | □分析师会议 | | | | | | | □现场参观 | 其他 电话会议 | | | | | | 参与单位名称及 | | 中金公司、玖鹏资产、中海基金、银华基金、中信期货资管、 | | | | | | 人员姓名 | 长江资管、招商自营、中泰自营等 | 48 家机构 | | | | | ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-22 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------------|------------------------|-------------------------------------------------------------|------------------------|-------|-------|------------------------------------------------------|-------|----------|-------| | 投资者关系活动 \n类别 | 特定对象调研 \n□现场参观 □其他 | | □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | | | | ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 编号：2022-23 | --- | --- | --- | --- | --- | |----------------|---------------------------------------------------|------------------------------------------------------|------------------|-------| | | | | | | | | 特定对象调研 | □分析师会议 | | | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | | | 类别 | | □新闻发布会 □路演活动 | | | | | □现场参观 □其他 | | | | | | 招商证券 | 许菲菲、王艺颖 | | | | 参与单位名称及 | 菁英时代 | 郑宇冰、李梦玉 | | | | 人员姓名 | 华创证券 高岳、张泉 | | | | | | 财通资管 冯雪云 | 德邦基金 揭诗琪 | | | | | 2022 年 9 月 21 | 日下午 15:00-16:30 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-24 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------|------------------------------|--------| | 投资者关系活动 | 特定对象调研 \n□媒体采访 □业绩说明会 | | | | 类别 | □新闻发布会 □路演活动 | | | | | □现场参观 □其他 | | | | 参与单位名称及 | 玖歌投资 孙健 | | | | 人员姓名 | 中金公司 刘锡源 德邦资管 | 郝晓婧 凯丰投资 | 裴彦春 | | 时间 | 2022 年 9 月 23 日上午 2022 年 9 月 23 日下午 | | | | | 地点 公司会议室 | | | | 上市公司接待人 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-25 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------------------------------------------------|------------------------------------------------|-------|-------|-------|-------|-----------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 □其他 | □分析师会议 | | | | | | | ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-26 | --- | --- | --- | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------|-------|------------------|-------| | 投资者关系活动 类别 | □特定对象调研 \n□现场参观 | □分析师会议 \n□媒体采访 □业绩说明会 □新闻发布会 □路演活动 \n 其他 线上调研 | | | | | | | 中信建投证券 | 阳明春；南方基金 谢巍；景顺长城基金 | | | | 姜雪 | | 参与单位名称及 人员姓名 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-21 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------|-------|----------------|-------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 | □分析师会议 \n 其他 线上调研 | | | | | | 参与单位名称及 | 金世富盈、环球时刻（北京）、国盛证券 | 6 | | | 位机构投资者代 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 编号：2022-27 | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------------|------------------------------------------------------|--------------------|------------| | 投资者关系活动 | □特定对象调研 \n□媒体采访 □业绩说明会 | □分析师会议 | | | | 类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | 其他 2022 | 年第三季度业绩说明 | | | 参与单位名称及 | 电话会议 | 德邦证券、平安证券、首创证券、申万宏源、方正证券、安 | | | | 人员姓名 | 证券等 88 位机构及个人投资者 | 信基金、华夏基金、国泰基金、玖歌投资、彤源投资、招商 | | | | 时间 2022 | 年 10 月 28 日下午 | 15:00-15:40 | ...

Financial Performance - The company's revenue for Q3 2022 reached ¥568,212,860.39, representing a 42.82% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥78,622,110.11, up 39.41% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥77,176,911.73, reflecting a 46.25% increase from the previous year[5] - The company reported a total of ¥90,259,643.84 in trading financial assets, down from ¥100,314,246.58[18] - The net profit for the third quarter was 208,389,289.18, an increase of 23.1% compared to 169,211,746.27 in the same period last year[32] - Operating profit reached 231,054,782.41, up from 187,884,885.27, reflecting a growth of 22.9% year-over-year[32] - Total revenue from operating activities was 1,740,154,700.95, compared to 1,268,663,192.10, marking a year-over-year increase of 37.1%[33] - The total profit for the period was 230,472,568.29, compared to 187,535,180.75, showing an increase of 22.9% year-over-year[32] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,038,665,448.50, a 16.81% increase from the end of the previous year[5] - The company's total liabilities reached CNY 774,739,577.46, compared to CNY 645,899,203.77, marking an increase of 19.9%[25] - Non-current liabilities rose to CNY 414,086,794.87, up from CNY 275,523,196.97, indicating a 50.4% increase[25] - The equity attributable to shareholders increased to CNY 1,263,925,871.04 from CNY 1,099,337,578.54, a growth of 15%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥166,513,197.28, showing a significant increase of 73.87%[10] - Cash flow from operating activities generated a net amount of 166,513,197.28, compared to 95,766,161.00 in the previous year, indicating a significant improvement[36] - Investment activities resulted in a net cash outflow of -285,124,174.85, compared to -242,069,533.61 in the same period last year[36] Shareholder Information - The top shareholder, Zhu Zhihong, holds 35.75% of shares, totaling 117,474,000 shares[14] - The second-largest shareholder, Duan Lixin, owns 14.78% of shares, amounting to 48,561,005 shares[14] - The company has a total of 10,086 common stock shareholders at the end of the reporting period[14] Research and Development - The company's R&D expenses for the period were ¥128,529,979.49, which is a 41.70% increase due to new R&D projects[10] - Research and development expenses were CNY 128,529,979.49, representing a 41.7% increase from CNY 90,708,588.17 year-over-year[26] Current Assets - Total current assets as of September 30, 2022, amounted to ¥1,070,000,000, a decrease from ¥1,200,000,000 at the beginning of the year[18] - Cash and cash equivalents decreased to ¥322,894,203.81 from ¥398,405,362.65, reflecting a decline of approximately 19%[18] - Accounts receivable increased significantly to ¥370,068,745.49 from ¥248,853,047.33, representing a growth of about 48.5%[18] - Inventory rose to ¥264,520,420.81, up from ¥214,478,519.60, indicating an increase of approximately 23.3%[18] - Other receivables increased to ¥3,151,993.75 from ¥2,150,570.41, marking a rise of approximately 46.5%[18] Operating Costs - Total operating costs amounted to CNY 1,367,842,381.56, up 43.8% from CNY 951,368,579.56 in the prior period[26] - The company reported a significant increase in sales expenses, which totaled CNY 817,858,940.49, up from CNY 567,383,854.88, reflecting a 44.0% rise[26] Credit Impairment - The company experienced a 73.03% increase in credit impairment losses, primarily due to an increase in accounts receivable[10] - The company incurred credit impairment losses of -7,036,771.77, which increased from -4,066,792.83 in the previous year[32]